Gsa Capital Partners LLP Pro Qr Therapeutics N.V. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$1.3 - $1.77 $39,322 - $53,538	30,248 Added 69.0%	74,084 $96,000
Q2 2023 Aug 14, 2023	BUY	$1.62 - $2.32 $71,014 - $101,699	43,836 New	43,836 $71,000
Q4 2022 Feb 13, 2023	BUY	$0.8 - $3.7 $17,211 - $79,601	21,514 New	21,514 $80,000
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $901,479 - $1.16 Million	-137,003 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.16 - $8.47 $390,684 - $641,297	75,714 Added 123.54%	137,003 $1.15 Million
Q2 2021 Aug 05, 2021	BUY	$5.75 - $7.59 $202,037 - $266,689	35,137 Added 134.36%	61,289 $413,000
Q1 2021 May 10, 2021	SELL	$4.14 - $9.22 $88,898 - $197,981	-21,473 Reduced 45.09%	26,152 $173,000
Q4 2020 Feb 03, 2021	BUY	$3.58 - $4.85 $170,497 - $230,981	47,625 New	47,625 $200,000
Q4 2019 Feb 12, 2020	SELL	$5.84 - $10.51 $65,589 - $118,037	-11,231 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$5.76 - $9.44 $64,690 - $106,020	11,231 New	11,231 $65,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.